Targeted Anticoagulation for Atrial Fibrillation Guided by Continuous Rhythm Assessment With an Insertable Cardiac Monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) Pilot Study
Rod Passman(Northwestern University), Peter Zimetbaum(Beth Israel Deaconess Medical Center), Anna Huskin(Northwestern Memorial Hospital), Todd T. Tomson(Northwestern Memorial Hospital), Jonathan W. Waks(Beth Israel Deaconess Medical Center), Adin‐Cristian Andrei(University of Michigan), Richard A. Bernstein(Northwestern University), E. Ellis(Beth Israel Deaconess Medical Center), Peter Leong‐Sit(Western University)
Cited by 113
Related Papers
Cryptogenic Stroke and Underlying Atrial Fibrillation
|New England Journal of Medicine|2014|2.2k
Part 8: Adult Advanced Cardiovascular Life Support
|Circulation|2010|1.6k
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
|Kidney International|2011|928
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823